Apr 26 |
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
|
Apr 24 |
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
|
Apr 24 |
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
|
Apr 16 |
Turnstone Biologics Appoints William Waddill to its Board of Directors
|
Apr 16 |
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
|
Apr 7 |
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
|
Apr 4 |
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
|
Apr 4 |
Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
|
Apr 1 |
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
|
Mar 30 |
Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
|